利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

41 条记录 (耗时 0.03 秒)

    ACE2-TARGETED COMPOSITIONS AND METHODS FOR TREATING COVID-19
    1.
    发明申请
    ACE2-TARGETED COMPOSITIONS AND METHODS FOR TREATING COVID-19 审中-公开

    公开(公告)号：WO2023064757A1

    公开(公告)日：2023-04-20

    申请号：PCT/US2022/077889

    申请日：2022-10-11

    申请人： MADDON ADVISORS LLC

    发明人： MADDON, Paul J.

    IPC分类号： A61K39/395 ,  C07K16/40 ,  C07K16/46 ,  C12N15/13

    摘要： This invention provides a monoclonal antibody that (i) specifically binds to the extracellular portion of human angiotensin converting enzyme 2 (hACE2); (ii) specifically inhibits binding of SARS-CoV-2 to the extracellular portion of hACE2; and (iii) does not significantly inhibit the ability of hACE2 to cleave angiotensin II and/or a synthetic MCA-based peptide. This invention also provides related recombinant AAV vectors, recombinant AAV particles, compositions, prophylactic and therapeutic methods, and kits.

    LOW DOSE ANTIBODY-BASED METHODS FOR TREATING HEMATOLOGIC MALIGNANCIES
    3.
    发明申请
    LOW DOSE ANTIBODY-BASED METHODS FOR TREATING HEMATOLOGIC MALIGNANCIES 审中-公开
    低剂量抗体为基础的治疗血液恶性肿瘤的方法

    公开(公告)号：WO2017205587A1

    公开(公告)日：2017-11-30

    申请号：PCT/US2017/034406

    申请日：2017-05-25

    申请人： ACTINIUM PHARMACEUTICALS, INC.

    发明人： CICIC, Dragan

    IPC分类号： C07K16/28 ,  A61K51/10 ,  A61P35/02 ,  A61K39/00

    摘要： This invention provides a method for treating a subject afflicted with a hematologic malignancy comprising administering to the subject an agent targeting a hematologic malignancy-associated antigen, wherein the subject has a low peripheral cancerous cell burden. This invention also provides a method for treating a subject afflicted with a hematologic malignancy and having a high peripheral cancerous cell burden, comprising (i) medically lowering the subject's peripheral cancerous cell burden, and (ii) while the subject's peripheral cancerous cell burden is still low, administering to the subject an agent targeting a hematologic malignancy-associated antigen. Particularly envisioned are the subject methods for treating acute myeloid leukemia using an anti-CD33 antibody labeled with an alpha-emitting isotope, such as 225 Ac-HuM195.

    摘要翻译： 本发明提供了治疗患有血液恶性肿瘤的受试者的方法，包括向所述受试者施用靶向血液恶性肿瘤相关抗原的药剂，其中所述受试者具有低外周癌性细胞负荷。 本发明还提供了一种治疗患有恶性血液病且周围癌细胞负荷高的受试者的方法，其包括（i）医学上降低受试者的外周癌细胞负荷，和（ii）当受试者的外周癌细胞负荷仍然 低，向受试者施用靶向血液恶性肿瘤相关抗原的药剂。 特别设想的是使用用α发射同位素标记的抗CD33抗体如225-Ac-HuM195治疗急性骨髓性白血病的主题方法。

    NICOTINE DERIVATIVES AND METHODS OF USE
    4.
    发明申请
    NICOTINE DERIVATIVES AND METHODS OF USE 审中-公开
    NICOTINE衍生物和使用方法

    公开(公告)号：WO2015183530A1

    公开(公告)日：2015-12-03

    申请号：PCT/US2015/030068

    申请日：2015-05-11

    申请人： GOODMAN, Jory, F.

    发明人： GOODMAN, Jory, F.

    IPC分类号： A61K31/465 ,  C07D401/04 ,  A61P25/26

    CPC分类号： A61K31/465 ,  A61K31/137 ,  A61K31/198 ,  A61K31/519 ,  A61K45/06 ,  C07D401/04

    摘要： This invention provides a compound selected from the group consisting of L- nicotine(X 1 )(X 2 ) and D-nicotine(X 1 )(X 2 ), or a pharmaceutically acceptable salt thereof, wherein (i) each of Χ 1 and X 2 is independently a pharmaceutically acceptable anion or a null set; and (ii) Χ 1 and X 2 cannot both be null sets. This invention also provides related compositions, as well as methods for treating a disorder reasonably believed to be ameliorated by the administration of nicotine.

    摘要翻译： 本发明提供了选自L-尼古丁（X1）（X2）和D-尼古丁（X1）（X2）的化合物或其药学上可接受的盐，其中（i）X 1和X 2各自独立地为 药学上可接受的阴离子或无效集合; 和（ii）X 1和X 2不能都是空集合。 本发明还提供了相关组合物，以及用于治疗合理认为通过施用尼古丁来改善的病症的方法。

    MCT PROTEIN INHIBITOR-RELATED PROGNOSTIC AND THERAPEUTIC METHODS
    6.
    发明申请
    MCT PROTEIN INHIBITOR-RELATED PROGNOSTIC AND THERAPEUTIC METHODS 审中-公开
    MCT蛋白抑制剂相关预防和治疗方法

    公开(公告)号：WO2013112881A1

    公开(公告)日：2013-08-01

    申请号：PCT/US2013/023209

    申请日：2013-01-25

    申请人： THOMAS JEFFERSON UNIVERSITY

    发明人： LISANTI, Michael, P. ,  SOTGIA, Federica

    IPC分类号： G01N33/574 ,  A61K31/519 ,  A61P35/00

    CPC分类号： A61K31/519 ,  G01N33/57407 ,  G01N33/57492 ,  G01N33/6872 ,  G01N2333/705 ,  G01N2800/52

    摘要： This invention provides a method of identifying one or more subgroups of cancer patients that are likely to benefit from treatment with a monocarboxylate transporter (MCT) protein inhibitor comprising: (a) obtaining a sample of a cancer/tumor tissue from each of said cancer patients; (b) determining the expression level of stromal MCT4 protein in each of said samples of cancer/tumor tissue to obtain a first dataset; and (c) using the expression level of the stromal MCT4 protein from said first dataset to classify each of said sets of one or more cancer patients as stromal MCT4-positive or stromal MCT4-negative, wherein the cancer patients classified as stromal MCT4- positive are patients that are more likely to benefit from treatment with said MCT protein inhibitor. This invention also provides related methods for treating a cancer/tumor whose stromal component expresses the MCT4 protein in a patient.

    摘要翻译： 本发明提供一种鉴定可能受益于单羧酸转运蛋白（MCT）蛋白抑制剂的癌症患者的一个或多个亚组的方法，该方法包括：（a）从每个所述癌症患者获得癌症/肿瘤组织的样品 ; （b）确定每个所述癌/肿瘤组织样品中基质MCT4蛋白的表达水平以获得第一数据集; 和（c）使用来自所述第一数据集的基质MCT4蛋白的表达水平将所述一组或多种癌症患者组中的每一组分类为基质MCT4阳性或基质MCT4阴性，其中分类为基质MCT4阳性的癌症患者 是更有可能受益于用所述MCT蛋白抑制剂治疗的患者。 本发明还提供了治疗患者中基质成分表达MCT4蛋白的癌/肿瘤的相关方法。

    COMPOSITIONS AND METHODS FOR TREATING MORPHINE, HEROIN, AND ALCOHOL DEPENDENCE
    8.
    发明申请
    COMPOSITIONS AND METHODS FOR TREATING MORPHINE, HEROIN, AND ALCOHOL DEPENDENCE 审中-公开

    公开(公告)号：WO2021242821A1

    公开(公告)日：2021-12-02

    申请号：PCT/US2021/034197

    申请日：2021-05-26

    申请人： BEHNAM, Babak

    发明人： AKBARZADEHKHIAVI, Azim ,  KHAVARI, Afshin

    IPC分类号： A61K39/385 ,  A61K47/48 ,  C07K16/44

    摘要： This invention provides a composition of matter comprising a plurality of morphine-6-succinyl-BSA, wherein the average ratio of morphine-6-succinyl moieties to BSA is at least 7.0. This invention also provides a composition of matter comprising a plurality of heroin-6-succinyl-BSA, wherein the average ratio of heroin-6-succinyl moieties to BSA is at least 7.0. This invention further provides a composition of matter comprising a plurality of ethanol-succinyl-BSA, wherein the average ratio of ethanol-succinyl moieties to BSA is at least 7.0. This invention still further provides related pharmaceutical compositions, therapeutic methods, prophylactic methods, synthetic methods, and articles of manufacture.

    Microsphere-Based Injectible Celecoxib Formulation
    10.
    发明申请
    Microsphere-Based Injectible Celecoxib Formulation 审中-公开

    公开(公告)号：WO2021026289A1

    公开(公告)日：2021-02-11

    申请号：PCT/US2020/045099

    申请日：2020-08-06

    申请人： AVIDENCE THERAPEUTICS, INC.

    发明人： LI, Ang

    IPC分类号： A61K36/575 ,  A61K47/12 ,  A61Q1/00

    摘要： This invention provides a biodegradable microsphere, wherein the microsphere (i) has a diameter of from 1 ?m to 500 ?m; (ii) comprises a polylactic-co-glycolic acid copolymer (PLGA) matrix; (iii) carries pharmaceutical celecoxib; and (iv) when present in a suitable joint-related tissue, releases celecoxib for at least one month. This invention also provides related injectable formulations, methods for treating joint-related disorders, and kits.